Tempus AI Expands Cancer Therapy Collaboration with Moderna and Merck
Tempus AI has expanded its multi-year collaboration with Moderna and Merck & Co. to support the potential commercialization of intismeran autogene, an individualized cancer therapy. The partnership involves Tempus managing tumor and blood samples as part of a broader effort in precision oncology research. The deal underscores growing interest in personalized medicine within the biopharmaceutical industry. Moderna's mRNA technology combined with Merck’s expertise in oncology is being leveraged to develop innovative treatments, while Tempus contributes its data analytics capabilities for sample management and insights generation. This expansion reflects a strategic alignment among key players aiming to advance cancer therapies through cutting-edge research and collaboration.
